Optimizing Outcomes in the Management of Multiple Myeloma: Key Managed Care Considerations on the Evolving Role of Anti-CD38 Therapy

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2023 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2023 to August 1, 2024
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Sanofi

Description:
Multiple myeloma (MM) is a systemic malignancy of plasma cells that is highly treatable but rarely curable. The median survival in the prechemotherapy era was about 7 months however new and emerging treatment options are currently undergoing late stage clinical trials and have shown great outcomes and real-world data in their ability to improve clinical and economic outcomes. MM is staged by estimating the myeloma tumor cell mass on the basis of the amount of monoclonal (or myeloma) protein (M protein) in the serum and/or urine, along with various clinical parameters, such as the hemoglobin and serum calcium concentrations, amongst other factors. The stage of the disease at presentation is a strong determinant of survival, but it has little influence on the choice of therapy since almost all patients, except for rare patients with solitary bone tumors or extramedullary plasmacytomas, have generalized disease. Treatment selection is influenced by the age and general health of the patient, prior therapy, and the presence of complications of the disease. Treatment is directed at reducing the tumor cell burden and reversing any complications of disease, such as renal failure, infection, hyperviscosity, or hypercalcemia with appropriate medical management. MM remains a disease with poor long-term survival as it is currently incurable and all patients will eventually relapse, underlining the need for new therapies. This webcast activity will take a close look at the evolving role of anti-CD38 monoclonal antibodies in the management of relapsed/refractory multiple myeloma.


Upon completion of this activity, participants will be able to:

• Assess the clinical and economic burden of multiple myeloma (MM), including factors that contribute to poor prognosis and increased costs

• Explain the impact of disease-specific factors, risk assessment, and treatment history on therapy decision-making in multiple myeloma

• Compare and contrast recent clinical trial data from studies that assessed anti-CD38 monoclonal antibody therapy, and their combinations, for newly diagnosed and relapsed/refractory multiple myeloma

• Identify patients with newly diagnosed or relapsed/refractory MM for whom treatment with an anti-CD38 therapeutic regimen would be appropriate

• Evaluate practical strategies to recognize and manage adverse events related to anti-CD38 combination therapy use in multiple myeloma

• Assess managed care considerations of anti-CD38 monoclonal antibody therapy by exploring where these agents fit in both the current newly diagnosed and relapsed/refractory multiple myeloma management paradigm
  
  
   

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)^TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Sanofi

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue